BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-10-25 05:00 |
BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS
|
English | 120.7 KB | ||
| 2022-10-25 05:00 |
BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS
|
English | 3.9 KB | ||
| 2022-10-11 05:00 |
BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1…
|
English | 121.5 KB | ||
| 2022-10-11 05:00 |
BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1…
|
English | 4.9 KB | ||
| 2022-09-27 13:02 |
BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT…
|
English | 111.1 KB | ||
| 2022-09-27 13:02 |
BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT…
|
English | 6.0 KB | ||
| 2022-09-07 05:00 |
BerGenBio to Present at Pareto Securities' 13th Annual Healthcare Conference
|
English | 117.5 KB | ||
| 2022-09-07 05:00 |
BerGenBio to Present at Pareto Securities' 13th Annual Healthcare Conference
|
English | 2.5 KB | ||
| 2022-08-23 05:00 |
BerGenBio reports second quarter and half year 2022 financial results and provi…
|
English | 6.9 MB | ||
| 2022-08-23 05:00 |
BerGenBio reports second quarter and half year 2022 financial results and provi…
|
English | 235.8 KB | ||
| 2022-08-23 05:00 |
BerGenBio reports second quarter and half year 2022 financial results and provi…
|
English | 9.7 KB | ||
| 2022-08-09 05:00 |
BERGENBIO ASA: Invitation to second quarter and half year 2022 results webcast
|
English | 109.2 KB | ||
| 2022-08-09 05:00 |
BERGENBIO ASA: Invitation to second quarter and half year 2022 results webcast
|
English | 2.9 KB | ||
| 2022-06-16 10:58 |
BerGenBio - Mandatory notification of trade by Primary Insider
|
English | 125.7 KB | ||
| 2022-06-16 10:58 |
BerGenBio - Mandatory notification of trade by Primary Insider
|
English | 1.2 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
